A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors

Bibliographic Details
Main Authors:	Nathan, P, Judson, I, Padhani, A, Harris, A, Sinha, R, Jane, B, Smythe, J, Fisher, N, Taylor, J, Collins, D, Connors, H, Gordon, R
Format:	Journal article
Published:	2007

Similar Items